Inovio Pharmaceuticals, Inc.
http://www.inovio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inovio Pharmaceuticals, Inc.
Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
COVID-19 Vaccines Blaze New Path In the History Of Vaccine Development
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
Synairgen Supercharges R&D With $100m Financing
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Stockwatch: Batsu Games − Drug And Vaccine Development
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- ADMET
- Bioinformatics
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Bioject Medical Technologies
- Inovio Biomedical
- VGX Pharmaceuticals